Harikrishnan Vijayakumar Sreelatha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Harikrishnan Vijayakumar Sreelatha has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Klas Stig Peter Abelson
University of Copenhagen
3 shared publications Lissy K. Krishnan
Division of Thrombosis Research, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology
3 shared publications- Lissy Kalliyana Krishnan
Division of Thrombosis Research, Department of Applied Biology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, India
3 shared publications A. Sabareeswaran
Division of Experimental Pathology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology
2 shared publicationsAnil Arya
Division of Laboratory Animal Science, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology
2 shared publicationsHamza Palekkodan
Department of Veterinary Pathology, College of Veterinary and Animal Sciences, Pookot, Wayanad, Kerala, India
2 shared publications
Latest Publications
- 1 August 2026
- Published by IOP Publishing in Biomedical Materials
- Vol. 21 (4) , 049501
CORRIGENDUM: Optimizing fibrin hydrogel toward effective neural progenitor cell delivery in spinal cord injury (2022 Biomed. Mater. 17 014102)
CORRIGENDUM: Optimizing fibrin hydrogel toward effective neural progenitor cell delivery in spinal cord injury (2022 Biomed. Mater. 17 014102), Sudhadevi, Tara, Vijayakumar, Harikrishnan S, Hariharan, Easwer V, Sandhyamani, Samavedam, Krishnan, Lissy K
- 1 August 2026
- Published by IOP Publishing in Biomedical Materials
- Vol. 21 (4) , 049501
CORRIGENDUM: Optimizing fibrin hydrogel toward effective neural progenitor cell delivery in spinal cord injury (2022 Biomed. Mater. 17 014102)
CORRIGENDUM: Optimizing fibrin hydrogel toward effective neural progenitor cell delivery in spinal cord injury (2022 Biomed. Mater. 17 014102), Sudhadevi, Tara, Vijayakumar, Harikrishnan S, Hariharan, Easwer V, Sandhyamani, Samavedam, Krishnan, Lissy K
- Open Access
Introducing the technique of group-handling in C57BL/6NCrl mice using a novel device “Citizen- Chitra Mus-Mobile”, a cage-transfer cum enrichment system, reduces stress, anxiety and time taken for cage changes and enhances voluntary interaction
It has been proven that tail-lifting mice can cause stress, anxiety and aversive behavior, and this finding has made scientists develop less stressful techniques like cupping and tunnel- handling. All these techniques have a disadvantage in that they can only handle mice individually and not in groups. This study produces scientific evidence on the advantages of group handling of laboratory mice for the first time. Group handling using the novel device significantly reduced the time taken and number of attempts taken for cage changes, a major reason that prevented tunnel-handling from being adopted globally. Shifting mice in groups using a device named “Mus-Mobile” resulted in significantly lower fecal corticosteroid levels, higher voluntary interaction time and the open field activity and time spent in the central arena were not altered when compared with tail lifting and tunnel handling in C57BL/6NCrl mice. Body weights were also not different when Mus-Mobile was employed with respect to the other groups. This work shows that group-shifting is the next horizon for animal welfare, as this device can revolutionize the handling of laboratory mice to bring in better animal wellbeing.
Open AccessIntroducing the technique of group-handling in C57BL/6NCrl mice using a novel device “Citizen- Chitra Mus-Mobile”, a cage-transfer cum enrichment system, reduces stress, anxiety and time taken for cage changes and enhances voluntary interaction
It has been proven that tail-lifting mice can cause stress, anxiety and aversive behavior, and this finding has made scientists develop less stressful techniques like cupping and tunnel- handling. All these techniques have a disadvantage in that they can only handle mice individually and not in groups. This study produces scientific evidence on the advantages of group handling of laboratory mice for the first time. Group handling using the novel device significantly reduced the time taken and number of attempts taken for cage changes, a major reason that prevented tunnel-handling from being adopted globally. Shifting mice in groups using a device named “Mus-Mobile” resulted in significantly lower fecal corticosteroid levels, higher voluntary interaction time and the open field activity and time spent in the central arena were not altered when compared with tail lifting and tunnel handling in C57BL/6NCrl mice. Body weights were also not different when Mus-Mobile was employed with respect to the other groups. This work shows that group-shifting is the next horizon for animal welfare, as this device can revolutionize the handling of laboratory mice to bring in better animal wellbeing.
- 4 April 2024
- Published by Springer Nature
- p. 17-28
Ethics, Welfare, 3Rs, and Legislation in Biomedical Research: A Practical Approach
- 4 April 2024
- Published by Springer Nature
- p. 17-28
Ethics, Welfare, 3Rs, and Legislation in Biomedical Research: A Practical Approach
- 4 April 2024
- Published by Springer Nature
- p. 77-128
Basic Techniques to Facilitate Small Animal Experimentation
- 4 April 2024
- Published by Springer Nature
- p. 77-128
Basic Techniques to Facilitate Small Animal Experimentation
- Open Access
- 16 January 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (1) , e0294720
Refinement of the motorised laminectomy-assisted rat spinal cord injury model by analgesic treatment
Usage and reporting of analgesia in animal models of spinal cord injury (SCI) have been sparse and requires proper attention. The majority of experimental SCI research uses rats as an animal model. This study aimed to probe into the effects of some commonly used regimens with NSAIDs and opioids on well-being of the rats as well as on the functional outcome of the model. This eight-week study used forty-two female Wistar rats (Crl: WI), randomly and equally divided into 6 treatment groups, viz. I) tramadol (5mg/kg) and buprenorphine (0.05mg/kg); II) carprofen (5mg/kg) and buprenorphine (0.05mg/kg); III) carprofen (5mg/kg); IV) meloxicam (1mg/kg) and buprenorphine (0.05mg/kg); V) meloxicam (1mg/kg); and VI) no analgesia (0.5 ml sterile saline). Buprenorphine was administered twice daily whereas other treatments were given once daily for five days post-operatively. Injections were given subcutaneously. All animals underwent dental burr-assisted laminectomy at the T10-T11 vertebra level. A custom-built calibrated spring-loaded 200 kilodynes force deliverer was used to induce severe SCI. Weekly body weight scores, Rat Grimace Scale (RGS), and dark-phase home cage activity were used as markers for well-being. Weekly Basso Beattie and Bresnahan (BBB) scores served as markers for functionality together with Novel Object Recognition test (NOR) at week 8 and terminal histopathology using area of vacuolisation and live neuronal count from the ventral horns of spinal cord. It was concluded that the usage of analgesia improved animal wellbeing while having no effects on the functional aspects of the animal model in comparison to the animals that received no analgesics.
- 16 January 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (1) , e0294720
Open AccessRefinement of the motorised laminectomy-assisted rat spinal cord injury model by analgesic treatment
Usage and reporting of analgesia in animal models of spinal cord injury (SCI) have been sparse and requires proper attention. The majority of experimental SCI research uses rats as an animal model. This study aimed to probe into the effects of some commonly used regimens with NSAIDs and opioids on well-being of the rats as well as on the functional outcome of the model. This eight-week study used forty-two female Wistar rats (Crl: WI), randomly and equally divided into 6 treatment groups, viz. I) tramadol (5mg/kg) and buprenorphine (0.05mg/kg); II) carprofen (5mg/kg) and buprenorphine (0.05mg/kg); III) carprofen (5mg/kg); IV) meloxicam (1mg/kg) and buprenorphine (0.05mg/kg); V) meloxicam (1mg/kg); and VI) no analgesia (0.5 ml sterile saline). Buprenorphine was administered twice daily whereas other treatments were given once daily for five days post-operatively. Injections were given subcutaneously. All animals underwent dental burr-assisted laminectomy at the T10-T11 vertebra level. A custom-built calibrated spring-loaded 200 kilodynes force deliverer was used to induce severe SCI. Weekly body weight scores, Rat Grimace Scale (RGS), and dark-phase home cage activity were used as markers for well-being. Weekly Basso Beattie and Bresnahan (BBB) scores served as markers for functionality together with Novel Object Recognition test (NOR) at week 8 and terminal histopathology using area of vacuolisation and live neuronal count from the ventral horns of spinal cord. It was concluded that the usage of analgesia improved animal wellbeing while having no effects on the functional aspects of the animal model in comparison to the animals that received no analgesics.
- 1 June 2023
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 101 (6) , 304-315
Pharmacological safety of dimethoxy curcumin-human serum albumin conjugate for potential therapeutic purpose
Medicinal properties of curcumin are widely published. Previously, researchers used curcuminoid mixture comprising three chemical forms, out of which, the highest quantity is the most active molecule—dimethoxy curcumin (DMC). Reduced bioavailability, poor aqueous solubility, and quick hydrolytic degradation of DMC have projected challenges limiting its therapeutic value. However, selective conjugation of DMC with human serum albumin (HSA) enhances drug stability and solubility by several folds. Studies using animal models demonstrated potential anti-cancer/anti-inflammatory effects of DMCHSA; both studies showed results of local administration in peritoneal cavity and rabbit knee joint. DMC has prospects as intravenous therapeutic agent because carrier is HSA. However, before in vivo testing, important preclinical data required are toxicological safety and bioavailability of soluble forms of DMC. This study evaluated absorption, distribution, metabolism, and excretion of DMCHSA. Imaging technology and molecular analysis proved bio-distribution. The study also assessed the pharmacological safety of DMCHSA in mice in terms of its acute and sub-acute toxicity, complying with regulatory toxicology. Overall, the study demonstrated the safety pharmacology of DMCHSA upon intravenous infusion. This is a novel study establishing the safety of highly soluble and stable formulation of DMCHSA, qualifying it for intravenous administration and further efficacy evaluation in suitable disease models.
- 1 June 2023
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 101 (6) , 304-315
Pharmacological safety of dimethoxy curcumin-human serum albumin conjugate for potential therapeutic purpose
Medicinal properties of curcumin are widely published. Previously, researchers used curcuminoid mixture comprising three chemical forms, out of which, the highest quantity is the most active molecule—dimethoxy curcumin (DMC). Reduced bioavailability, poor aqueous solubility, and quick hydrolytic degradation of DMC have projected challenges limiting its therapeutic value. However, selective conjugation of DMC with human serum albumin (HSA) enhances drug stability and solubility by several folds. Studies using animal models demonstrated potential anti-cancer/anti-inflammatory effects of DMCHSA; both studies showed results of local administration in peritoneal cavity and rabbit knee joint. DMC has prospects as intravenous therapeutic agent because carrier is HSA. However, before in vivo testing, important preclinical data required are toxicological safety and bioavailability of soluble forms of DMC. This study evaluated absorption, distribution, metabolism, and excretion of DMCHSA. Imaging technology and molecular analysis proved bio-distribution. The study also assessed the pharmacological safety of DMCHSA in mice in terms of its acute and sub-acute toxicity, complying with regulatory toxicology. Overall, the study demonstrated the safety pharmacology of DMCHSA upon intravenous infusion. This is a novel study establishing the safety of highly soluble and stable formulation of DMCHSA, qualifying it for intravenous administration and further efficacy evaluation in suitable disease models.
- 13 February 2023
- Published by Springer Nature in 3 Biotech
- Vol. 13 (3) , 1-12
Enriched adipose stem cell secretome as an effective therapeutic strategy for in vivo wound repair and angiogenesis
The therapeutic potential of adipose tissue-derived mesenchymal stem cells (ADMSCs) is well studied for use in non-healing wounds. However, concerns on the transplantable cell number requirement, cell expansion, cell viability, retained cell multipotency and the limited cell implantation time for efficient impact hinders cell therapy. Recent literature is much inclined to the superiority of the ADMSCs’ secretome, pre-dominating its paracrine-mediated therapeutic impact. In this context, the possibility of attaining accelerated wound angiogenesis through non-viral mediated enrichment of the ADMSCs secretome with pro-angiogenic growth factors (AGF) seems promising. Accordingly, this study aimed to explore the effect of AGF-enriched ADMSCs secretome for accelerating wound angiogenesis and repair in acute large area full thickness excision rabbit wound model, as adopted from Salgado et al. (Chir Buchar Rom 108:706–710, 1990). Using sub-dermal single-dose injections along the margin of the dorsal wound, native ADMSCs secretome, AGF-enriched ADMSC secretome, allogenic rabbit ADMSCs and a combination of AGF-enriched ADMSC secretome with allogenic rabbit ADMSCs were transplanted independently. Twenty-eight days (28 days) post-transplantation, histopathological analysis was performed to assess the effect. Hematoxylin and eosin (H&E) staining showed enhanced epithelization, notable granulation tissue and collagen fiber deposition in AGF-enriched secretome transplanted groups. This was confirmed by elevated CD31 detection, faster wound closure time and collagen organization. The use of single-dose AGF-enriched ADMSCs’ secretome for therapeutic angiogenesis and wound repair seems to be a promising cell-free therapeutic option. Further investigations using multiple doses on larger animal groups remains to be explored in order to ascertain the comparative potential of AGF-enriched ADMSCs’ secretome.
- 13 February 2023
- Published by Springer Nature in 3 Biotech
- Vol. 13 (3) , 1-12
Enriched adipose stem cell secretome as an effective therapeutic strategy for in vivo wound repair and angiogenesis
The therapeutic potential of adipose tissue-derived mesenchymal stem cells (ADMSCs) is well studied for use in non-healing wounds. However, concerns on the transplantable cell number requirement, cell expansion, cell viability, retained cell multipotency and the limited cell implantation time for efficient impact hinders cell therapy. Recent literature is much inclined to the superiority of the ADMSCs’ secretome, pre-dominating its paracrine-mediated therapeutic impact. In this context, the possibility of attaining accelerated wound angiogenesis through non-viral mediated enrichment of the ADMSCs secretome with pro-angiogenic growth factors (AGF) seems promising. Accordingly, this study aimed to explore the effect of AGF-enriched ADMSCs secretome for accelerating wound angiogenesis and repair in acute large area full thickness excision rabbit wound model, as adopted from Salgado et al. (Chir Buchar Rom 108:706–710, 1990). Using sub-dermal single-dose injections along the margin of the dorsal wound, native ADMSCs secretome, AGF-enriched ADMSC secretome, allogenic rabbit ADMSCs and a combination of AGF-enriched ADMSC secretome with allogenic rabbit ADMSCs were transplanted independently. Twenty-eight days (28 days) post-transplantation, histopathological analysis was performed to assess the effect. Hematoxylin and eosin (H&E) staining showed enhanced epithelization, notable granulation tissue and collagen fiber deposition in AGF-enriched secretome transplanted groups. This was confirmed by elevated CD31 detection, faster wound closure time and collagen organization. The use of single-dose AGF-enriched ADMSCs’ secretome for therapeutic angiogenesis and wound repair seems to be a promising cell-free therapeutic option. Further investigations using multiple doses on larger animal groups remains to be explored in order to ascertain the comparative potential of AGF-enriched ADMSCs’ secretome.
- 20 February 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (6) , 1565-1576
Pharmacokinetics and Pharmacodynamics of Avian Egg-Yolk Derived Pure Anti-Snake Venom in Healthy and Disease Animal-Model
- 20 February 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (6) , 1565-1576
Pharmacokinetics and Pharmacodynamics of Avian Egg-Yolk Derived Pure Anti-Snake Venom in Healthy and Disease Animal-Model